Replies to post #10737 on ProtoKinetix Inc (PKTX)

[GJ1212]

I do understand the sometimes difficult legalities. My question was more ..... if you can't name the global company for 3 weeks or a month then so be it. You can see the problem this caused with shareholders. As a result the share price took a 40% drop when it should have taken a 40% up-tick. As you know we all worked really really hard to get it to $.27 !!!
Why not just hold off on the PR until the company can be named ?

[gosox12]

Thanks for your reply. There is more to this issue, however, than simply whether the partner can be named or not.

The Press Release does not say that we've signed a contract and that some kind of payment has been received from the partner. Instead, it says, "we've engaged" the services etc. of a global company.

So, it seems to me that we can conclude that we've in fact hired them and it is us who are paying them for their services. Couple that with the fact that the partner cannot even be named, and it seems to me that this is far from the deal we longs were hoping would start seriously moving the share price. And then throw in the important point that we have no info on how long all these developmental steps are going to take before even getting a decision from the FDA on a Phase I trial. All this suggests that the dry-eye results to date have not put us in a terribly strong bargaining position.

My main hope now is that the 5 years or so of pre-clinical work that Dr. Evans has been doing on macular degeneration will get us an impressive big pharma deal which, hopefully, could happen at any time.

Comments welcome.